CAS 7636-26-2|(DL)-3-O-Methyldopa
| Common Name | (DL)-3-O-Methyldopa | ||
|---|---|---|---|
| CAS Number | 7636-26-2 | Molecular Weight | 211.214 |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 407.3±45.0 °C at 760 mmHg |
| Molecular Formula | C10H13NO4 | Melting Point | / |
| MSDS | / | Flash Point | 200.1±28.7 °C |
Names
| Name | 2-Amino-3-(4-hydroxy-3-methoxyphenyl)propanoic acid |
|---|---|
| Synonym | More Synonyms |
(DL)-3-O-Methyldopa BiologicalActivity
| Description | 3-O-Methyl-DL-DOPA is an endogenous metabolite present in Cerebrospinal_Fluid that can be used for the research of Epilepsy, Purine Nucleoside Phosphorylase Deficiency and Aromatic L Amino Acid Decarboxylase Deficiency[1][2][3][4]. |
|---|---|
| Related Catalog | Research Areas >>Neurological Disease |
| In Vitro | Endogenous metabolites is defined as those that are annotated by Kyoto Encyclopedia of Genes and Genomes as substrates or products of the ~1900 metabolic enzymes encoded in our genome. It is clear in the body of literature that there are documented toxic properties for many of these metabolites[1]. |
| References | [1]. Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug;39(35):5709-5720. [2]. Darin N, et al. Mutations in PROSC Disrupt Cellular Pyridoxal Phosphate Homeostasis and Cause Vitamin-B6-Dependent Epilepsy. Am J Hum Genet. 2016 Dec 1;99(6):1325-1337. [3]. Ormazabal A, et al. Pyridoxal 5'-phosphate values in cerebrospinal fluid: reference values and diagnosis of PNPO deficiency in paediatric patients. Mol Genet Metab. 2008 Jun;94(2):173-7. [4]. Abdenur JE, et al. Aromatic l-aminoacid decarboxylase deficiency: unusual neonatal presentation and additional findings in organic acid analysis. Mol Genet Metab. 2006 Jan;87(1):48-53. |
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 407.3±45.0 °C at 760 mmHg |
| Molecular Formula | C10H13NO4 |
| Molecular Weight | 211.214 |
| Flash Point | 200.1±28.7 °C |
| Exact Mass | 211.084457 |
| PSA | 92.78000 |
| LogP | 0.08 |
| Vapour Pressure | 0.0±1.0 mmHg at 25°C |
| Index of Refraction | 1.591 |
| InChIKey | PFDUUKDQEHURQC-UHFFFAOYSA-N |
| SMILES | COc1cc(CC(N)C(=O)O)ccc1O |
Safety Information
| Risk Phrases | 22-36/37/38 |
|---|---|
| Safety Phrases | 22-26-36/37/39 |
| RIDADR | NONH for all modes of transport |
Articles25
More Articles| Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients. Mov. Disord 26 , 543-546, (2011) Oxidative stress is influenced by the thiol homeostasis, which determines the redox milieu. One of its components is Cysteinyl-glycine (Cys-Gly) generation, as its metabolic precursor is the free radi... | |
| Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Clin. Neuropharmacol. 33(3) , 135-41, (2010) The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluat... | |
| Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. Eur. J. Neurol. 19(6) , 820-6, (2012) Catechol-O-methyltransferase inhibitors may be used to decrease levodopa requirement. The objective was to investigate whether the levodopa/carbidopa intestinal gel infusion dose can be reduced by 20%... |
Synonyms
| 3-Methoxytyrosine |
| 3-Methoxy-D,L-tyrosine |
| 2-amino-3-(4-hydroxy-3-methoxyphenyl)propanoic acid |
| 3-Methoxy-tyrosine |
| Tyrosine, 3-methoxy- |
| 3-METHOXY-DL-TYROSINE |
| UNII:SO86T1OB2P |
| 3-O-Methyldopa |
